Israel Active

Allocetra from Israel’s Enlivex (see previously) saved many patients suffering from Covid-19 and sepsis. Clinical trials have now begun, using it to treat patients with advanced solid tumors. Allocetra reprograms immune system macrophages that cause cancer.

Israel’s Precise Bio is developing 3D-printed synthetic corneas and retinas to enable visually impaired people to see clearly again. Precise Bio takes donated cells, grows them in the lab, and then 3D-prints them onto a biological scaffold. Looking forward to news of future clinical trials.

The JNF-USA has established an emergency response center in Sapir in the Israel’s southern Arava / Negev region. The new state of the art command station will provide tourists and residents in this desert region with rescue, fire-fighting and other emergency services.

YonaLink bridges the gap between patient care and clinical research, providing the missing link in clinical trials data collection by connecting the patient’s Electronic Health Record (ERC) to the clinical trials’ data capture system, without disrupting the trial.

The US FDA has cleared the SUPERB™ technology of Israel’s Sofwave Medical (see previously) for the short-term improvement in the appearance of cellulite. The approval followed a successful multi-center US efficacy and safety trial.

In a first-of-its-kind study, researchers at Tel Aviv University equipped some 4,700 Israelis with smartwatches and monitored them physiologically over two years. None of the 2,000+ who received the coronavirus booster vaccine registered or reported heart-related or other serious side effects.

Some 15 percent of the world’s most influential studies on COVID-19 vaccines were written by Israeli scientists - 536 from Jan 2020 to Jun 2022. In the major medical journals (New England Journal of Medicine and Nature Medicine), Israel was third and fourth respectively.

Back in 2020, Israel’s Sheba Medical Center partnered with the US National Institutes of Health (NIH – see previously) to research Coronavirus treatments. They have now extended their partnership to include any emerging pathogens and the rapid deployment of scientific tools to fight them.

A study led by Tel Aviv University scientists has uncovered nearly 100,000 types of viruses that were previously unknown to science. The discovery may help in the development of antimicrobial treatments and in protecting against agriculturally harmful fungi and parasites.

Israel’s Nanosono has developed an antimicrobial platform based on zinc oxide and copper oxide that permanently eliminates disease-causing pathogens from products and surfaces. Nanosono has partnered with Israel’s Gadot Group, which will build Nanosono’s production line infrastructure in Israel.